948897-63-0

Upstream product

• 65515-28-8 methyl 2,6-dichloronicotinate 
• 2100-42-7 2-chloro-1,4-dimethoxybenzene 
• 925207-28-9 methyl 6-(4-chloro-phenoxy)-2-propylnicotinate 
• 948897-61-8 C₁₅H₁₄ClNO₃ 
• 38496-18-3 2,6-dichloropyridine-3-carboxylic acid 
• 906794-87-4 methyl 2-chloro-6-(4-chlorophenoxy)nicotinate 
• 948897-62-9 C₂₃H₂₁Cl₂NO₄ 

Downstream Products

• 909543-30-2 (2S)-2-({6-chloro-3-[6-(4-chlorophenoxy)-2-propylpyridin-3-yl]-1,2-benzisoxazol-5-yl}oxy)propanoic acid 
• 948897-60-7 (2S)-2-({6-chloro-3-[6-(4-chlorophenoxy)-2-propylpyridin-3-yl]-1,2-benzisoxazol-5-yl}oxy)propanoic acid benzenesulfonate salt 
• 948897-66-3 (2S)-2-({6-chloro-3-[6-(4-chlorophenoxy)-2-propylpyridin-3-yl]-1,2-benzisoxazol-5-yl}oxy)propanoic acid tosylate salt 
• 948897-70-9 C₇H₈O₃S*C₂₁H₁₆Cl₂N₂O₃ 

Relevant academic research and scientific papers

NOVEL CRYSTALLINE SALT FORM OF AN ANTIDIABETIC COMPOUND

A novel crystalline anhydrous toluenesulfonic acid salt form of a selective PPAR gamma partial agonist which has a fused bicyclic aromatic group attached to an oxypropanoic acid moiety is stable and non-hygroscopic. The crystalline salt form is useful for

NOVEL CRYSTALLINE FORMS OF ANTIDIABETIC COMPOUNDS

A novel crystalline anhydrate of the free acid and a crystalline anhydrous besylate salt of a selective PPAR gamma partial agonist which has a fused bicyclic aromatic group attached to an oxypropanoic acid moiety are stable and non-hygroscopic. The compou

FUSED AROMATIC COMPOUNDS HAVING ANTI-DIABETIC ACTIVITY

Fused aromatic compounds of Formula (I) are PPAR gamma agonists or partial agonists and are useful in the treatment or control of type II diabetes, including hyperglycemia, dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, and obes